Innovive Pharmaceuticals, Inc.
Cancer immunotherapeutic licensed from Memorial Sloan-Kettering Cancer Center
Published in Physician Law Weekly, February 8th, 2006
Innovive anticipates commencing phase I trials in the first half of 2006 to study the immunotherapeutic (INNO-305) in the treatment of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), non small cell lung cancer (NSCLC) and mesothelioma.
WT1 is expressed in most leukemias and in a variety of solid tumors. WT1 expression is a known indicator of poor outcome in acute leukemia.
INNO-305 is unique among WT1 peptide cancer immunotherapeutics...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2006-02-08)
More Articles from Physician Law Weekly
- Acacia Research Corporation
CombiMatrix to become independent public company - Advanced BioPhotonics Inc.
Medical imaging company restructures and reduces board of directors - AngioDynamics, Inc.
Peter J. Graham appointed to board of directors at cardiology-focused device firm - Antisense Therapeutics
Approval granted to restart phase IIa trial of antisense compound in MS patients - Aperio Technologies
Microscopy systems company hires regulatory affairs executive - Bioterrorism
Law firm introduces report on new Terrorism Risk Insurance Extension Act - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
